78 related articles for article (PubMed ID: 6180419)
1. [B-DOPA chemotherapy associated with local radiotherapy in children with malignant lymphoma].
Armata J; Legutko L
Pol Tyg Lek; 1982 Apr; 37(7):193-5. PubMed ID: 6180419
[No Abstract] [Full Text] [Related]
2. The cure of Hodgkin's disease with drugs.
DeVita VT; Hubbard SM; Moxley JH
Adv Intern Med; 1983; 28():277-302. PubMed ID: 6188346
[No Abstract] [Full Text] [Related]
3. [Lymphomas. Treatment of malignant lymphomas. Current observations and future prospects].
Klastersky J
Rev Med Brux; 1982 Apr; 3(4):223-34. PubMed ID: 6178138
[No Abstract] [Full Text] [Related]
4. [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():33-9. PubMed ID: 15688474
[TBL] [Abstract][Full Text] [Related]
5. MOPP, ABVD, or both to treat Hodgkin's disease.
Martino R; Nomdedeu J; Brunet S
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
[No Abstract] [Full Text] [Related]
6. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of recurrences of Hodgkin's disease in children].
Armata J; Moryl-Bujakowska A
Pol Tyg Lek; 1983 Oct 17-24; 38(42-43):1301-4. PubMed ID: 6201835
[No Abstract] [Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
9. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
10. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
Constine LS
J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
[No Abstract] [Full Text] [Related]
11. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
[TBL] [Abstract][Full Text] [Related]
12. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
Kamieńska E
Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
[TBL] [Abstract][Full Text] [Related]
13. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
[TBL] [Abstract][Full Text] [Related]
14. [Hodgkin disease and amyloidosis].
Jekunen A; Maiche A; Laurila P; Franssila K; Elomaa I
Duodecim; 1994; 110(6):602-6. PubMed ID: 7555860
[No Abstract] [Full Text] [Related]
15. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
16. Hodgkin's disease. Treatment of resistant patients.
De Lena M; Santoro A
Cancer Clin Trials; 1979; 2(1):83-5. PubMed ID: 93032
[No Abstract] [Full Text] [Related]
17. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
19. A new combination chemotherapy for recurrent Hodgkin's lymphoma.
Rahim MA; Sarma SK; Ahmed Q
Bangladesh Med Res Counc Bull; 1982 Dec; 8(2):63-7. PubMed ID: 6897860
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: a Southwest Oncology Group Phase II Study.
Miller TP; Jones SE; Rainey JM
Cancer Treat Rep; 1983; 67(7-8):739-40. PubMed ID: 6688200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
